Panacea Biotec files suit seeking to restrain Sanofi from marketing fully liquid hexavalent vaccine

18 May 2021 Evaluate

Panacea Biotec has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine. A case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

407.05 48.55 (13.54%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×